http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021013061-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b6d40e044398947e5899630aa24f6402 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-22 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-475 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-22 |
| filingDate | 2020-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39f5dd766ee0bebe61715565c4bcacd6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ce924ae107e045208d6c45838d92402 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b906ec4e3b3f087e64c99a62e979cfdd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_33c5f15d0a726bc3b311ceff9596c37d |
| publicationDate | 2021-01-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2021013061-A1 |
| titleOfInvention | Humanized anti-vegfr2 antibody and application thereof |
| abstract | Provided is a humanized anti-VEGFR2 antibody drug. Also provided are a nucleic acid sequence (comprising a heavy/light chain variable region) encoding the antibody, a vector containing the nucleic acid sequence, a pharmaceutical composition, and a kit. The antibody can specifically bind to the sixth structural domain of VEGFR2, exerts a function independent of ligand VEGF-A, and can directly inhibit VEGFR2 from forming a dimer, thereby blocking tyrosine residue phosphorylation caused by the dimerization of an intracellular domain of VEGFR2 and a downstream signaling pathway. In addition, the antibody keeps a function of partially blocking VEGF-C and VEGF-D, and thus has a better angiogenesis inhibition function. The antibody can also activate the occurrence of an antibody-dependent cell-mediated cytotoxicity (ADCC) reaction in NK cells, inhibits tumor growth and tumor metastases, and can be used for clinically treating melanomas. |
| priorityDate | 2019-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 158.